These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20523864)

  • 1. Recent advances in pharmacotherapy of atrial fibrillation.
    Singh J; Braich JS
    Indian J Pharmacol; 2009 Aug; 41(4):153-7. PubMed ID: 20523864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiarrhythmic Drug Therapy for Rhythm Control in Atrial Fibrillation.
    Waks JW; Zimetbaum P
    J Cardiovasc Pharmacol Ther; 2017 Jan; 22(1):3-19. PubMed ID: 27260643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the management of atrial fibrillation.
    Anis RR
    Exp Clin Cardiol; 2009; 14(1):e1-7. PubMed ID: 19492029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiarrhythmic drugs for atrial fibrillation: lessons from the past and opportunities for the future.
    Heijman J; Hohnloser SH; Camm AJ
    Europace; 2021 Apr; 23(23 Suppl 2):ii14-ii22. PubMed ID: 33837753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmic drug therapy for atrial fibrillation: focus on atrial selectivity and safety.
    Li D; Sun H; Levesque P
    Cardiovasc Hematol Agents Med Chem; 2009 Jan; 7(1):64-75. PubMed ID: 19149545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.
    Savelieva I; Kakouros N; Kourliouros A; Camm AJ
    Europace; 2011 Mar; 13(3):308-28. PubMed ID: 21345926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiarrhythmic therapy following ablation of atrial fibrillation.
    Stabile G; Iuliano A; Agresta A; La Rocca V; D'Ascia S; De Simone A
    Expert Rev Cardiovasc Ther; 2013 Jul; 11(7):837-42. PubMed ID: 23895027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel approaches for pharmacological management of atrial fibrillation.
    Ehrlich JR; Nattel S
    Drugs; 2009; 69(7):757-74. PubMed ID: 19441867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have no beneficial effect on ablation outcome in chronic persistent atrial fibrillation.
    Zheng B; Kang J; Tian Y; Tang R; Long D; Yu R; He H; Zhang M; Shi L; Tao H; Liu X; Dong J; Ma C
    Acta Cardiol; 2009 Jun; 64(3):335-40. PubMed ID: 19593943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of antiarrhythmic drugs to maintain sinus rhythm after catheter ablation for atrial fibrillation: a meta-analysis.
    Xu X; Alida CT; Yu B
    Cardiovasc Ther; 2015 Aug; 33(4):242-6. PubMed ID: 26031448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardioversion for atrial fibrillation: treatment options and advances.
    Reiffel JA
    Pacing Clin Electrophysiol; 2009 Aug; 32(8):1073-84. PubMed ID: 19659629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological approaches in the treatment of atrial fibrillation.
    Tamargo J; Caballero R; Delpón E
    Curr Med Chem; 2004 Jan; 11(1):13-28. PubMed ID: 14754423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Need for ongoing anti arrhythmic drugs after ablation of atrial fibrillation. Review.
    Salghetti F; Vizzardi E; Elmaghawry M; Mamedouv R; D'Aloia A; Bonadei I; Sciatti E; Lipari A; Cerini M; Bontempi L; Metra M; Curnis A
    Recent Pat Cardiovasc Drug Discov; 2013 Dec; 8(3):204-15. PubMed ID: 24359232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization.
    Singh BN; Mody FV; Lopez B; Sarma JS
    Am J Cardiol; 1999 Nov; 84(9A):161R-173R. PubMed ID: 10568677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis.
    Healey JS; Baranchuk A; Crystal E; Morillo CA; Garfinkle M; Yusuf S; Connolly SJ
    J Am Coll Cardiol; 2005 Jun; 45(11):1832-9. PubMed ID: 15936615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic management of atrial fibrillation: established and emerging options.
    Kalus JS
    J Manag Care Pharm; 2009 Aug; 15(6 Suppl B):S10-8. PubMed ID: 19678722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New approaches to atrial fibrillation management: a critical review of a rapidly evolving field.
    Nattel S; Khairy P; Roy D; Thibault B; Guerra P; Talajic M; Dubuc M
    Drugs; 2002; 62(16):2377-97. PubMed ID: 12396229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
    Lafuente-Lafuente C; Longas-Tejero MA; Bergmann JF; Belmin J
    Cochrane Database Syst Rev; 2012 May; (5):CD005049. PubMed ID: 22592700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-antiarrhythmic drugs to prevent atrial fibrillation.
    Moro C; Hernández-Madrid A; Matía R
    Am J Cardiovasc Drugs; 2010; 10(3):165-73. PubMed ID: 20524718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.